L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote
14 mai 2024 05h53 HE
|
ALLIANCE PROMOTION MICROBIOTE
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote Paris - France – 14 mai...
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
14 mai 2024 05h53 HE
|
ALLIANCE PROMOTION MICROBIOTE
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector Paris - France - May 14, 2024 -...
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee
14 mai 2024 03h00 HE
|
Nouscom Srl
Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that...
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
13 mai 2024 16h00 HE
|
Fractyl Health, Inc.
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions
13 mai 2024 09h00 HE
|
Beacon Biosignals
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals announced a strategic partnership with Longboard Pharmaceuticals, Inc. that combines Longboard’s drug development expertise with Beacon’s...
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
13 mai 2024 08h00 HE
|
Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
13 mai 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
13 mai 2024 07h00 HE
|
Tourmaline Bio, Inc.
Tourmaline Bio announces financial results and business highlights for the first quarter ended March 31, 2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
13 mai 2024 06h05 HE
|
AC Immune SA
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for...
Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
13 mai 2024 05h30 HE
|
Hummingbird Bioscience
Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.